Paratek Pharma buy Quitte
Start price
02.03.17
/
50%
€14.25
Target price
10.04.17
€20.20
Performance (%)
43.35%
End price
10.04.17
€20.43
Summary
This prediction ended on 10.04.17 with a price of €20.43. The BUY prediction by Quitte for Paratek Pharma saw massive gains of 43.35%. Quitte has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Paratek Pharma | - | - | - | - |
| iShares Core DAX® | -0.793% | 4.201% | 19.951% | 70.602% |
| iShares Nasdaq 100 | -2.376% | 0.857% | 4.704% | 103.322% |
| iShares Nikkei 225® | -2.701% | -0.147% | 12.609% | 44.593% |
| iShares S&P 500 | -1.689% | 1.244% | 3.144% | 64.741% |
Comments by Quitte for this prediction
In the thread Paratek Pharma diskutieren
sieht doch gut aus
Stand 2. März 2017
BOSTON (AP) _ Paratek Pharmaceuticals Inc. (PRTK) on Thursday reported a loss of $26.5 million in its fourth quarter.
The Boston-based company said it had a loss of $1.16 per share.
The results beat Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of $1.29 per share.
The pharmaceutical company posted revenue of $29,000 in the period.
For the year, the company reported that its loss widened to $111.6 million, or $5.51 per share. Revenue was reported as $29,000.
Paratek shares have decreased roughly 2 percent since the beginning of the year. The stock has dropped nearly 3 percent in the last 12 months.